Total Funding
28
44
Total FundingVenture - Series Unknown raised
Growth Score
-8 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
53110
ImaginAb clinically manages cancer and autoimmune diseases via molecular imaging by re-engineering antibodies into small proteins.
Acquired by 
Telix Pharmaceuticals
Anna M. Wu: FounderPast Role: Beckman Research Institute, Professor- William Le: Vice President, Operations
Telix Pharmaceuticals
About the Company
ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical
trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.
Women Founded
